as on November 17, 2025 at 11:40 pm IST
Day's Low
Day's High
2.50%
Downside
1.07%
Upside
52 Week's Low
52 Week's High
61.85%
Downside
129.95%
Upside
Check Kalaris Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$45.3M
EPS (TTM)
-5.255
Dividend Yield
0.00%
PE Ratio (TTM)
0PEG Ratio
0Return On Equity TTM
0.00%
Compare market cap, revenue, PE, and other key metrics of Kalaris Therapeutics Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| NA | $45.3M | NA | NA | 0.00% | |
| BUY | $60.0B | 247.38% | 1448.9 | 1.36% | |
| NA | $43.9B | NA | 717.29 | 1.38% | |
| BUY | $110.9B | 96.07% | 30.76 | 31.35% | |
| BUY | $73.0B | 28.87% | 16.61 | 32.13% |
Search interest for Kalaris Therapeutics Inc Stock has decreased by -63% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
![]()
In the last 7 days, KLRS stock has moved up by 13.7%
Against Peers
![]()
In the last 1 year, Beone Medicines Ltd has given 93.3% return, outperforming this stock by 151.6%
Against Peers
![]()
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 82.4% return, outperforming this stock by 179.1%
| Organisation | Kalaris Therapeutics Inc |
| Headquarters | 628 Middlefield Road, Palo Alto, CA, United States, 94301 |
| CEO | Mr. Andrew Oxtoby |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Dr. Srinivas Akkaraju M.D., Ph.D. | Director & Co-Founder |
Dr. Michael Philip Dybbs Ph.D. | Director & Co-Founder |
Dr. Napoleone Ferrara M.D. | Independent Director & Co-Founder |
Mr. Matthew Gall M.B.A. | CFO & Treasurer |
Mr. Brett R. Hagen | Chief Accounting Officer |
Dr. Matthew Feinsod M.D. | Chief Medical Officer |
Ms. Kristine Curtiss | Senior Vice President of Clinical |
Mr. Andrew Oxtoby | President, CEO & Director |
Kalaris Therapeutics Inc share price today is $5.61 as on . Kalaris Therapeutics Inc share today touched a day high of $5.67 and a low of $5.47.
Kalaris Therapeutics Inc share touched a 52 week high of $12.9 on and a 52 week low of $2.14 on . Kalaris Therapeutics Inc stock price today i.e. is trending at $5.61,which is 56.51% down from its 52 week high and 162.15% up from its 52 week low.
Kalaris Therapeutics Inc market capitalisation is $0.00T as on .
Indian investors can start investing in Kalaris Therapeutics Inc (KLRS) shares with as little as ₹88.613 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹886.13 in Kalaris Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Kalaris Therapeutics Inc share’s latest price of $5.61 as on November 17, 2025 at 11:40 pm IST, you will get 1.7825 shares of Kalaris Therapeutics Inc. Learn more about
fractional shares .